Lungs News and Research

RSS

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Allos Therapeutics, Inc. today announced that results from the Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress

10 Sep 2010

Researchers find risk prediction model for VTE in cancer patients

For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.

10 Sep 2010

Wealthy patients beat cancer better than poorer counterparts: Survey

Cancer survival rates have improved across England, according to two new reports from the Office for National Statistics (ONS).But the reports also reveal that there are still gaps in survival, with patients from wealthy areas having a better chance of beating cancer than their poorer counterparts.

10 Sep 2010

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

The wasting disease associated with some cancers that is typically seen affecting skeletal muscles can also cause significant damage to the heart, new research in mice suggests.

9 Sep 2010

Non-invasive test using patient's breath can detect cancer

A test using a patient's breath could be developed to detect lung, breast, bowel and prostate cancers, a team of scientists have discovered.While these results are only preliminary, the study published in the British Journal of Cancer today (Wednesday), found that sensors could distinguish between the breath of healthy patients and those who have cancer.

9 Sep 2010

Micro-RNAs programmed cells can lead to malignant growth

Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.

9 Sep 2010

NIH awards second $8 million grant for research into health effects of botanical estrogens

An ongoing research initiative into the health effects of botanical estrogens will get an $8 million boost from the National Institutes of Health.

9 Sep 2010

Texas Children's Hospital implants FDA approved transcatheter pulmonary heart valve

Using a newly FDA approved pulmonary valve, Dr. Frank Ing, director of the catheterization laboratory at Texas Children's Hospital and his team of pediatric interventional cardiologists implanted a transcatheter pulmonary heart valve into the heart of a 13-year-old girl, which spared her from having her chest opened for a third heart surgery.

9 Sep 2010

Ohio State University receives five-year grant to improve drug therapy using gene profiles

The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled "Expression Genetics in Drug Therapy." The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

9 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

Columbus Regional Hospital joins Indiana Network for Patient Care

Columbus Regional Hospital is bringing the nation's largest health information exchange to the Columbus, Ind. area to better serve patients. Joining over 65 hospitals, long term care facilities and other healthcare providers, Columbus Regional Hospital is now part of a statewide network that allows physicians to securely access necessary information to make decisions critical to patient care.

8 Sep 2010

Vitamin D may improve asthma: Report

Supplement your asthma action plan with Vitamin D and you may experience improved asthma control according to an article published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

8 Sep 2010

Reports on smoking rates among Americans reveal dramatic progress in fight against tobacco

Two new reports released today by the Centers for Disease Control and Prevention show that while the United States has made dramatic progress in the fight against tobacco, too many Americans still smoke and too many non-smokers including more than half of all young children are still exposed to secondhand smoke.

8 Sep 2010

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced that Israeli soldiers who suffer severe traumatic brain injury (TBI) can be enrolled in the company's Phase II-b STOP-TBI trials at clinical sites in Israel.

8 Sep 2010

NIH announces $15 million for expansion of Pharmacogenomics Knowledge Base

To help advance research on how genes affect responses to medicines, the National Institutes of Health is spending $15 million over five years to expand a key resource, the Pharmacogenomics Knowledge Base (PharmGKB), http://www.pharmgkb.org/ .

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

Obesity directly accelerates progression of acute lymphoblastic leukemia

The first study to demonstrate that obesity can directly accelerate the progression of acute lymphoblastic leukemia (ALL) has been conducted at The Saban Research Institute of Childrens Hospital Los Angeles and will be published in Cancer Prevention Research, on October 5, 2010. Obesity has been associated with an increased incidence of many cancers, including leukemia, but it has been unknown whether the increase in incidence was a direct effect of obesity or associated with genetic, lifestyle, health, or socio-economic factors.

8 Sep 2010

Biomoda joins Saccomanno Research Institute to advance CyPath technology for cancer detection

Cancer diagnostics company Biomoda, Inc. is working with the Saccomanno Research Institute to advance Biomoda's patented system for measuring the photon emission rate of CyPath-stained cells to detect early-stage lung cancer.

8 Sep 2010

Bruker launches Icon desktop MRI systems at 2010 World Molecular Imaging Congress

At the 2010 World Molecular Imaging Congress in Kyoto, Bruker Corporation today announces the introduction of the Icon™, a new easy-to-use 1 Tesla desktop MRI scanner that combines simplicity with compact dimensions, in order to bring preclinical magnetic resonance imaging (MRI) within reach for a broader range of molecular imaging laboratories.

7 Sep 2010

Axelar AB publishes first AXL1717 data on phase I/II cancer study

Axelar AB today announces that the first submitted medical article on the ongoing phase I/II cancer study with AXL1717 has been published in Acta Oncologica.

7 Sep 2010

Lungs News and Research

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Researchers find risk prediction model for VTE in cancer patients

Wealthy patients beat cancer better than poorer counterparts: Survey

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

Non-invasive test using patient's breath can detect cancer

Micro-RNAs programmed cells can lead to malignant growth

NIH awards second $8 million grant for research into health effects of botanical estrogens

Texas Children's Hospital implants FDA approved transcatheter pulmonary heart valve

Ohio State University receives five-year grant to improve drug therapy using gene profiles

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

Columbus Regional Hospital joins Indiana Network for Patient Care

Vitamin D may improve asthma: Report

Reports on smoking rates among Americans reveal dramatic progress in fight against tobacco

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

NIH announces $15 million for expansion of Pharmacogenomics Knowledge Base

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Obesity directly accelerates progression of acute lymphoblastic leukemia

Biomoda joins Saccomanno Research Institute to advance CyPath technology for cancer detection

Bruker launches Icon desktop MRI systems at 2010 World Molecular Imaging Congress

Axelar AB publishes first AXL1717 data on phase I/II cancer study

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News